Immunity to visceral leishmaniasis: implications for immunotherapy (Q38243220)

31 August 2017

title

Immunity to visceral leishmaniasis: implications for immunotherapy (English)

1 reference

31 August 2017

main subject

visceral leishmaniasis

1 reference

1 reference

2

Jude E Uzonna

1 reference

31 August 2017

1

Forough Khadem

1 reference

31 August 2017

publication date

1 January 2014

1 reference

31 August 2017

number of pages

15

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

31 August 2017

volume

9

1 reference

31 August 2017

issue

7

1 reference

31 August 2017

page(s)

901-915

1 reference

Leishmaniasis worldwide and global estimates of its incidence

31 August 2017

cites work

1 reference

A current perspective on leishmaniasis

21 January 2018

1 reference

Advances in leishmaniasis

21 January 2018

1 reference

The increase in risk factors for leishmaniasis worldwide

21 January 2018

1 reference

Old world leishmaniasis: an emerging infection among deployed US military and civilian workers

21 January 2018

1 reference

Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements

21 January 2018

1 reference

The biology and control of leishmaniasis vectors

21 January 2018

1 reference

Human immunodeficiency virus and leishmaniasis

21 January 2018

1 reference

Drug resistance in visceral leishmaniasis

21 January 2018

1 reference

Genetic typing and phylogeny of the Leishmania donovani complex by restriction analysis of PCR amplified gp63 intergenic regions.

21 January 2018

1 reference

Leishmaniasis: clinical syndromes and treatment

21 January 2018

1 reference

Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India

21 January 2018

1 reference

Visceral leishmaniasis mimicking autoimmune hepatitis, primary biliary cirrhosis, and systemic lupus erythematosus overlap

21 January 2018

1 reference

Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis

21 January 2018

1 reference

Visceral leishmaniasis in immunosuppressed Caucasian patient

21 January 2018

1 reference

Leishmaniasis in immunosuppressed individuals

21 January 2018

1 reference

Leishmaniasis in the United States: treatment in 2012

21 January 2018

1 reference

Treatment of visceral leishmaniasis

21 January 2018

1 reference

Current diagnosis and treatment of visceral leishmaniasis

21 January 2018

1 reference

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

21 January 2018

1 reference

Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study

21 January 2018

1 reference

High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B.

21 January 2018

1 reference

Liposomal amphotericin B for the treatment of visceral leishmaniasis

21 January 2018

1 reference

New antileishmanial candidates and lead compounds

21 January 2018

1 reference

Drug delivery strategies for therapy of visceral leishmaniasis

21 January 2018

1 reference

Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv.

21 January 2018

1 reference

Combination therapy for visceral leishmaniasis

21 January 2018

1 reference

Identification of TLR inducing Th1-responsive Leishmania donovani amastigote-specific antigens

21 January 2018

1 reference

What determines the success or failure of intracellular cutaneous parasites? Lessons learned from leishmaniasis

21 January 2018

1 reference

Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis

21 January 2018

1 reference

Balancing immunity and pathology in visceral leishmaniasis

21 January 2018

1 reference

21 January 2018

1 reference

Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis

21 January 2018

1 reference

Mast cells at the host-pathogen interface: host-protection versus immune evasion in leishmaniasis

21 January 2018

1 reference

Involvement of CD4⁺ Foxp3⁺ regulatory T cells in persistence of Leishmania donovani in the liver of alymphoplastic aly/aly mice

21 January 2018

1 reference

RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-gamma-primed macrophages

21 January 2018

1 reference

Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: role of TLR4 and TLR9.

21 January 2018

1 reference

Critical role of IRF-5 in the development of T helper 1 responses to Leishmania donovani infection

21 January 2018

1 reference

Toll-like receptors in leishmania infections: guardians or promoters?

21 January 2018

1 reference

Leishmania donovani Promastigotes Evade the Antimicrobial Activity of Neutrophil Extracellular Traps

21 January 2018

1 reference

Neutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani

21 January 2018

1 reference

Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver

21 January 2018

1 reference

The role of complement in the early phase of Leishmania (Leishmania) amazonensis infection in BALB/c mice.

21 January 2018

1 reference

Role of oxidative stress and apoptosis in the cellular response of murine macrophages upon Leishmania infection

21 January 2018

1 reference

Immunoactivation and immunopathogeny during active visceral leishmaniasis.

21 January 2018

1 reference

Leishmania Exosomes Modulate Innate and Adaptive Immune Responses through Effects on Monocytes and Dendritic Cells

21 January 2018

1 reference

CD8 cytotoxic T cells in cutaneous leishmaniasis

21 January 2018

1 reference

Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis

21 January 2018

1 reference

Identification of regulatory T cells during experimental Leishmania infantum infection

21 January 2018

1 reference

TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice

21 January 2018

1 reference

Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model.

21 January 2018

1 reference

Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania

21 January 2018

1 reference

The role of leishmania proteophosphoglycans in sand fly transmission and infection of the Mammalian host

21 January 2018

1 reference

Leishmania infantum proteophosphoglycans regurgitated by the bite of its natural sand fly vector, Lutzomyia longipalpis, promote parasite establishment in mouse skin and skin-distant tissues.

21 January 2018

1 reference

The immunopathology of experimental visceral leishmaniasis

21 January 2018

1 reference

Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology

21 January 2018

1 reference

TNF-induced signaling in apoptosis

21 January 2018

1 reference

Invasion and intracellular survival by protozoan parasites

21 January 2018

1 reference

An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macrophages

21 January 2018

1 reference

Leishmania GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases.

21 January 2018

1 reference

Activation of TGF-beta by Leishmania chagasi: importance for parasite survival in macrophages

21 January 2018

1 reference

Parasitic adaptive mechanisms in infection by leishmania

21 January 2018

1 reference

Leishmania major phosphoglycans influence the host early immune response by modulating dendritic cell functions

21 January 2018

1 reference

Leishmania donovani amastigotes impair gamma interferon-induced STAT1alpha nuclear translocation by blocking the interaction between STAT1alpha and importin-alpha5

21 January 2018

1 reference

Evasion of Host Defence by Leishmania donovani: Subversion of Signaling Pathways

21 January 2018

1 reference

Role of host protein tyrosine phosphatase SHP-1 in Leishmania donovani-induced inhibition of nitric oxide production

21 January 2018

1 reference

Vaccines to combat the neglected tropical diseases

21 January 2018

1 reference

Reduced hamster usage and stress in propagating Leishmania chagasi promastigotes using cryopreservation and saphenous vein inoculation

21 January 2018

1 reference

Development of Leishmania vaccines: predicting the future from past and present experience

21 January 2018

1 reference

Protective immunity and vaccination against cutaneous leishmaniasis.

21 January 2018

1 reference

Use of a LiESP/QA-21 vaccine (CaniLeish) stimulates an appropriate Th1-dominated cell-mediated immune response in dogs

21 January 2018

1 reference

Vaccination with LiESP/QA-21 (CaniLeish®) reduces the intensity of infection in Phlebotomus perniciosus fed on Leishmania infantum infected dogs--a preliminary xenodiagnosis study

21 January 2018

1 reference

Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis

21 January 2018

1 reference

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil

21 January 2018

1 reference

Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis.

21 January 2018

1 reference

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

21 January 2018

1 reference

Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals

21 January 2018

1 reference

Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease

21 January 2018

1 reference

Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis

21 January 2018

1 reference

Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.

21 January 2018

1 reference

Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis.

21 January 2018

1 reference

Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs

21 January 2018

1 reference

Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.

21 January 2018

1 reference

Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis

21 January 2018

1 reference

Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature.

21 January 2018

1 reference

Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment

21 January 2018

1 reference

Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.

21 January 2018

1 reference

Therapy of murine cutaneous leishmaniasis by DNA vaccination.

21 January 2018

1 reference

Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.

21 January 2018

1 reference

Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine.

21 January 2018

1 reference

Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine

21 January 2018

1 reference

Immunity and immunosuppression in experimental visceral leishmaniasis.

21 January 2018

1 reference

Interleukin-10 and the pathogenesis of human visceral leishmaniasis

21 January 2018

1 reference

Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis

21 January 2018

1 reference

Treatment with IP-10 induces host-protective immune response by regulating the T regulatory cell functioning in Leishmania donovani-infected mice.

21 January 2018

1 reference

In silico identification of conserved intercoding sequences in Leishmania genomes: unraveling putative cis-regulatory elements.

21 January 2018

1 reference

A proteogenomic approach to map the proteome of an unsequenced pathogen - Leishmania donovani

21 January 2018

1 reference

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis

21 January 2018

1 reference

Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FMB.14.43

1 reference

31 August 2017

1 reference